Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Selected Financial Data
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Income Statement

Merck & Co. Inc., selected items from income statement, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

The analysis of the financial data over the observed periods reveals several noteworthy trends regarding sales and net income attributable to Merck & Co., Inc.

Sales
Sales demonstrated a general upward trend throughout the years with some periods of fluctuation. Starting at approximately $22 billion in 2005, sales increased moderately through 2009, peaking significantly in 2010 at nearly $46 billion. This spike may indicate a major operational or market event.
Following 2010, sales stabilized around the $40 to $48 billion range with minor decreases and increases between years 2011 and 2018. From 2019 onwards, there was a pronounced growth, with sales rising from approximately $47 billion to over $64 billion by 2024, reflecting a strong positive momentum in revenue generation.
Net Income
Net income attributable to the company showed considerable volatility over the years compared to sales. Initial net income in 2005 was around $4.6 billion, followed by a slight decline and then a significant peak in 2008 at approximately $7.8 billion. This peak coincides with a relatively stable sales period.
A remarkable surge occurred in 2009, with net income reaching $12.9 billion, followed by a sharp decline to $861 million in 2010, despite sales spiking substantially that year. This indicates possible extraordinary expenses or one-time items affecting profitability.
From 2011 to 2014, net income fluctuated widely, showing declines and recoveries, reaching over $11.9 billion again in 2014. Subsequently, a general downward trend continued until 2017, with net income dropping below $2.5 billion, indicating a challenging profitability period.
Starting in 2018, net income began recovering, achieving over $9.8 billion in 2019. However, it fell again to $7.1 billion in 2020 but surged to $13 billion in 2021 and further to $14.5 billion in 2022, potentially reflecting improved operational efficiencies or favorable market conditions.
In 2023, net income sharply decreased to $365 million, an unusual deviation considering sales continued to increase. This sudden drop might be attributed to extraordinary losses or accounting adjustments. Subsequently, net income rebounded substantially to over $17 billion in 2024, marking the highest value in the data set.

Overall, while sales exhibited a mostly steady upward trajectory with substantial growth in the later years, net income displayed significant volatility with multiple peaks and troughs, suggesting that factors beyond sales volume notably influenced profitability over the period analyzed.


Balance Sheet: Assets

Merck & Co. Inc., selected items from assets, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

The analysis of the financial data reveals notable trends in both current assets and total assets over the examined period.

Current Assets
Current assets displayed a fluctuating pattern from 2005 through 2024. Starting at 21,049 million US$ in 2005, there was a decline to a low of 15,230 million US$ in 2006, followed by a stable range around 15,000 million US$ through 2007. A significant increase occurred in 2008 and 2009, peaking at 28,429 million US$, nearly doubling the 2007 figure. From 2010 to 2012, current assets continued to rise, reaching a high point of 34,857 million US$ in 2012. Subsequently, a gradual decline ensued from 2013 to 2017, bottoming at 24,766 million US$ in 2017. After 2017, there was a recovery phase with current assets growing again, exceeding previous highs and reaching 38,782 million US$ by the end of 2024. Overall, current assets showed a cyclical movement with a general upward trend in the latter years.
Total Assets
Total assets exhibited comparatively greater volatility and magnitude in values. Between 2005 and 2008, total assets remained relatively stable around 44,000 to 48,000 million US$. In 2009, a pronounced surge was recorded with total assets increasing sharply to 112,090 million US$. This elevated level was somewhat maintained through 2010 and 2011, though with a slight decline, before stabilizing around 105,000 million US$ between 2012 and 2015. Starting from 2016, total assets experienced a downward trend reaching a low of 82,637 million US$ in 2018. The period following 2018 saw a consistent recovery, with total assets rising again, surpassing 117,000 million US$ by 2024. This pattern suggests periods of expansion possibly attributable to asset acquisitions or revaluations, followed by strategic consolidations or divestitures and subsequent growth phases.

In summary, both current and total assets demonstrate significant cyclical behavior marked by notable peaks and troughs across the years. Despite interim declines, the general long-term movement reflects growth, particularly evident post-2017, indicating an improvement in asset base and liquidity position over time.


Balance Sheet: Liabilities and Stockholders’ Equity

Merck & Co. Inc., selected items from liabilities and stockholders’ equity, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

The annual financial data indicates several notable trends in the company's liabilities, debt, and equity positions over the analyzed period.

Current Liabilities
Current liabilities showed a general upward trend from 2005 through 2024, increasing from 13,304 million USD to 28,420 million USD. Some fluctuations occurred, with minor decreases in certain years (e.g., a drop from 18,766 million USD in 2013 to 17,204 million USD in 2016). However, the overall pattern is an increasing level, reflecting potentially higher short-term obligations or operational scale expansion.
Total Debt
Total debt exhibited greater volatility than current liabilities. Initially decreasing from 8,098 million USD in 2005 to 5,739 million USD in 2007, it then sharply increased to a peak of 25,060 million USD by 2013. After a brief decline, it surged again, reaching over 37,000 million USD by 2024. These fluctuations suggest periods of significant borrowing and debt refinancing, potentially to support strategic investments or acquisitions.
Stockholders’ Equity
The equity figures reveal considerable variability. From 17,917 million USD in 2005, equity rose sharply to 59,058 million USD in 2009, followed by a steady decrease to a low of 25,317 million USD in 2019. A notable recovery occurs during 2020 to 2022, reaching 45,991 million USD, before falling back down in 2023 and then rising again in 2024. This pattern may reflect fluctuations in retained earnings, share repurchases, dividend policies, or changes in comprehensive income.
Overall Financial Position
The simultaneous increase in both total debt and current liabilities alongside the fluctuating equity levels points to a dynamic capital structure. Increased debt levels in the later years imply greater leverage, which may be linked to financing strategies or operational needs. Equity volatility indicates impacts from either market valuation effects, operational performance, or capital management actions. The rise and fall in equity also suggest sensitivity to economic conditions or internal financial decisions.

Cash Flow Statement

Merck & Co. Inc., selected items from cash flow statement, long-term trends

US$ in millions

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Operating Activities Cash Flow

Net cash provided by operating activities shows notable fluctuations over the period analyzed. Initially, cash inflows were moderate, with values around $7.6 billion to $6.6 billion between 2005 and 2008. In 2009, there was a significant decline to approximately $3.4 billion, indicating possible operational challenges or increased working capital needs.

From 2010 onwards, operating cash flow exhibited recovery and growth, peaking in 2012 at about $12.4 billion. Although there are intermittent decreases in some years (2013, 2016, and 2020), the general trend involves strong cash flow generation, culminating in an all-time high near $21.5 billion by 2024. This overall positive trajectory suggests improved operational efficiency and successful revenue generation strategies.

Investing Activities Cash Flow

Cash flow from investing activities fluctuated significantly, often showing substantial outflows indicative of investment spending. Early years, particularly 2006 to 2008, were marked by heavy investment outflows reaching nearly -$6.8 billion in 2012.

In some years, positive cash flows from investing appear, such as in 2005, 2009, and 2017–2018, indicating asset sales or divestitures. However, large negative values dominate the timeline, peaking in outflow magnitude in 2020 at almost -$16.4 billion, likely reflecting increased capital expenditures, acquisitions, or R&D investments.

Post-2020, investing cash outflows reduce but remain significant. These patterns demonstrate a consistent and aggressive investment approach with episodic divestment activities.

Financing Activities Cash Flow

The net cash used in financing activities generally indicates cash outflows, suggesting debt repayments, dividend payments, or share repurchases. The period from 2005 through 2014 consistently displays negative values, with particularly large outflows around 2014, nearing -$15.1 billion, highlighting major financing cash uses during this time.

Contrastingly, there are isolated years showing positive inflows, notably in 2021, where cash provided by financing activities reached approximately $3.1 billion. This irregular inflow might be attributed to new debt issuance or equity financing.

Overall, the financing cash flows reflect a pattern of capital return to shareholders and debt management, with intermittent periods of raising capital.

Combined Cash Flow Analysis

The interplay of cash flows from operating, investing, and financing activities presents a picture of a company managing robust operational cash generation while actively investing in growth. The ability to sustain high operating cash flows facilitates heavy investing outflows without crippling liquidity.

The mixed and volatile financing cash flows suggest strategic capital structure adjustments and shareholder return policies adapting to market and business conditions. Significant investing outflows paired with strong operating inflows underpin a growth-focused financial policy.


Per Share Data

Merck & Co. Inc., selected data per share, long-term trends

US$

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1, 2, 3 Data adjusted for splits and stock dividends.

The analysis of the financial data reveals distinct trends over the examined period regarding earnings per share and dividends per share.

Basic Earnings Per Share (EPS)
Over the time frame, basic EPS demonstrated considerable volatility. Starting at a value above 2 US dollars in 2005, EPS showed a sharp decline in 2007 to below 1.6 US dollars. It then increased substantially in 2008 and 2009, peaking near 5.67 US dollars. This was followed by a significant drop in 2010 to 0.28 US dollars, suggesting an anomalous event impacting earnings. Subsequent years showed a pattern of fluctuation, with EPS oscillating between lows around 0.88 to highs above 5 US dollars. Notably, in 2022, EPS again dropped sharply to 0.14 US dollars before rebounding to 6.76 US dollars in 2024, marking the highest point in the series.
Diluted Earnings Per Share (EPS)
The diluted EPS closely follows the trend of basic EPS, with marginally lower values throughout the observed periods. The fluctuations mirror those found in basic EPS, indicating consistency in dilution effects and reinforcing the substantial variability in earnings over time. The lowest and highest points identified in basic EPS are similarly reflected here.
Dividend Per Share
Dividend per share exhibits a steady and consistent upward trend in contrast to the volatile EPS figures. Starting from 1.52 US dollars in 2005, dividends increased gradually every year, rising to 3.12 US dollars by 2024. This progression indicates a stable and growing cash return to shareholders, unaffected by the substantial earnings volatility seen in the other metrics.

Overall, the financial data shows a company experiencing significant fluctuations in profitability as measured by earnings per share, including periods of sharp decline and recovery. Meanwhile, the dividend policy appears conservative and progressively increasing, providing stability for investors despite earnings variability. This pattern could suggest a strategic emphasis on returning value to shareholders consistently even in years when earnings underperform.